$heff's $tation of $tocks & $olid DD

[lowman]

$heff, you were wise to advise to look elsewhere last time I mentioned TTPH here. However, the pps has now dropped well below their cash and equivalents value and deserves a second/closer look, or at least a spot on the watchlist.

TTPH had $222M cash as of 9/30/15 and currently trades at $155M market cap (36.5M o/s x 4.25).

Clearly, not even any consideration for the $250M+ they've expended in R&D on their pipeline, of which their lead candidate, eravacycline, met IGNITE 1 Phase 3 trials.


"As of September 30, 2015, Tetraphase had cash and cash equivalents of $222.5 million and 36.5 million shares outstanding. The company expects that its cash and cash equivalents, as well as expected revenue from its U.S. government awards, will be sufficient to fund operations into at least the first half of 2017."

"...increase in R&D expenses was primarily due to drug manufacturing and nonclinical costs in support of our NDA-related and pre-commercialization activities for eravacycline "


Fundies have been buying/adding a lot lately, too.

Vanguard Group: 2.062M sh (5.64%)
http://ih.advfn.com/p.php?pid=nmona&article=70326104


Blackrock: 3.015M sh (8.3%)
http://ih.advfn.com/p.php?pid=nmona&article=70152935


Wellington Management Group: 5.012M sh (13.72%)
http://ih.advfn.com/p.php?pid=nmona&article=70344743


Great Point Partners: 1.94M (5.3%)
http://ih.advfn.com/p.php?pid=nmona&article=69814475


State Street Corp: 3.66M (10.01%)
http://ih.advfn.com/p.php?pid=nmona&article=68864957

Short interest 6.012M (1/29/16)

(Because TTPH has no following to support it, the algo'bot has freely followed IBB and $DJI since the beginning of the year, totally ignoring fins and drug pipeline.)